Managed Care Weekly Digest
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Weekly Digest
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
Misonix expands distribution of visually directed HIFU for prostate cancer to Portugal
February 12th, 2007
Misonix, Inc. (MSON), a developer of ultrasonic medical device technology for the treatment of cancer and other chronic health conditions, announced that it has further expanded its European business of visually directed high intensity focused ultrasound (HIFU) using the Sonablate 500 for prostate cancer treatment with entry into Portugal. The Sonablate 500 (SB500) is a medical device developed by Focus Surgery, Inc. and manufactured by Misonix. Misonix also has the exclusive European distribution rights for the product. Misonix is an investor in privately held Focus Surgery, a prominent developer of HIFU. Misonix announced the signing of an...
Source: Managed Care Weekly Digest (2007-02-12)
|
